Incidence of COVID-19 Test Conversion in Post-surgical Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04392323|
Recruitment Status : Completed
First Posted : May 18, 2020
Last Update Posted : November 8, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 cases begins to decrease and hospital volume improves we need to ensure the safety of our patients planning surgical procedures. However, at this time there is a scarcity of data regarding the COVID-19 test conversion rate in surgical patients. Our goal is to determine the COVID-19 test conversion rate in these patients to better guide strategies for restarting surgical care in a large-scale pandemic.
Patients will be routinely tested with serology and PCR for COVID-19 24-48 hours prior to their scheduled surgery. Those who provide informed consent will be re-tested 12-16 days after discharge from the hospital to determine any potential nosocomial infection rate. Patients will also answer a few questions during their retest to allow the study team to gauge exposure risk postoperatively after leaving the hospital.
|Condition or disease||Intervention/treatment||Phase|
|Sars-CoV2||Diagnostic Test: COVID-19 PCR and Serology||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||111 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Prospective Cohort|
|Masking:||None (Open Label)|
|Official Title:||Incidence of COVID-19 Test Conversion in Post-surgical Patients|
|Actual Study Start Date :||May 13, 2020|
|Actual Primary Completion Date :||October 1, 2020|
|Actual Study Completion Date :||October 4, 2020|
Experimental: Study Group
Patients will be recruited as an outpatient prior to their surgical procedure or during their hospital admission. If they consent, they will provide signed informed consent and will receive testing with serology and PCR for COVID-19 infection at pre-surgical testing 24-48 hours prior to their scheduled procedure. If they consent while inpatient postoperatively, signed informed consent will be procured after they have completed their pre-operative COVID-19 testing. PCR for COVID entails obtaining a nasopharyngeal swab to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital.
Diagnostic Test: COVID-19 PCR and Serology
PCR for COVID entails obtaining a nasopharyngeal swab (a cotton tip introduced via the nose to obtain a sample) to determine whether there is active viral replication and viral shedding. They will then have a second test with serology and PCR for COVID-19 infection 12-16 days after discharge from the hospital. Serology implies that a blood sample will be obtained by venipuncture. A volume of 50 ml (about 4 tablespoons) or less of blood will be obtained.
- COVID-19 Test Conversion [ Time Frame: 14 days ]Patients that have negative pre-operative testing that convert to positive testing 14 days post-discharge
- Duration of Hospitalization [ Time Frame: 14 days ]Days from hospital admission to discharge.
- Rate of self-reported COVID-19 exposure [ Time Frame: 14 days ]Patients will be asked to describe if they have had any exposure to COVID-19 positive persons after their hospital stay.
- Rate of complications from COVID-19 [ Time Frame: 14 days ]If patients contract COVID-19 during the postoperative period, what complications occur?
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Patients of any ethnic background undergoing an elective surgical procedure with a minimum of 24-hour hospital admission.
- Age ≥18.
- Written Voluntary Informed Consent.
- Patients age < 18 years.
- Prior documented COVID-19 Infection.
- Current hospital inpatient prior to procedure.
- Person Under Investigation for COVID-19 infection.
- Current use of antiviral medications.
- Severe or uncontrolled, concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.) .
- Documented immunodeficiency.
- Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry.
- Outpatient procedures with planned same-day discharge.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04392323
|United States, New York|
|North Shore University Hospital|
|Manhasset, New York, United States, 10030|
|Long Island Jewish Medical Center|
|New Hyde Park, New York, United States, 11040|
|Principal Investigator:||Ernesto Molmenti, MD, PhD, MBA||Northwell Health|
|Principal Investigator:||Aaron Nizam, MD||Northwell Health|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Ernesto Molmenti, Vice Chairman of Surgery - Chief of Innovation. North Shore University Hospital, Northwell Health. Professor of Surgery, Medicine, and Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Northwell Health|
|Other Study ID Numbers:||
|First Posted:||May 18, 2020 Key Record Dates|
|Last Update Posted:||November 8, 2021|
|Last Verified:||May 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases